The conformational flexibility of the peptides to enter the hDHFR active site may help to selectively target the cancer cells due to the higher concentration of the enzyme (i.e., higher expression of DHFR) than in the normal tissues, and advantageously, the side effects associated with the use of hDHFR inhibitors as chemotherapeutics may be reduced. Here, DHFR is linked to cancer.